The epidemiological impact of HIV antiretroviral therapy on malaria in children

AIDS

Volumn 29, Issue 4, 2015, Pages 473-482

  Greenhalgh, Scott ^a   Ndeffo, Martial ^a   Galvani, Alison P ^a   Parikh, Sunil ^a  

^a Yale University Suite 200   (United States)

Author keywords

antimalarial effects of protease inhibitors; antiretrovirals; HIV; HIV malaria coinfection; HIV protease; inhibitors; lumefantrine; malaria; mathematical model; pharmacology

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; EPIDEMIOLOGICAL DATA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MALARIA; MATHEMATICAL MODEL; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; AFRICA SOUTH OF THE SAHARA; ANIMAL; DRUG COMBINATION; HIV INFECTIONS; IMMUNOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALARIA; RECURRENCE; TREATMENT OUTCOME;

EID: 84922402788     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000550     Document Type: Article

References (49)

1. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 2011; 11:541-556
2. Bositis CM, Gashongore I, Patel DM. Updates to the World Health Organizations recommendations for the use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Med J Zambia 2010; 37:111-117
3. WHO.ConsolidatedARV guidelines 2013.Geneva:WHO; 2013
4. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-2389
5. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral agents and prevention of malaria in HIVinfected Ugandan children. N Engl J Med 2012; 367:2110-2118
6. Tejerina F, Bernaldo de Quiro s JCL. Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients. AIDS Rev 2011; 13:227-233
7. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access: recommendations for a public health approach: 2010 revision. Geneva: WHO; 2010. http://apps.who.int/medicinedocs/en/d/Js18809en/. [accessed 6 November 2013].
8. Kuhn L, Hunt G, Technau K-G, Coovadia A, Ledwaba J, Pickerill S, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 2014; 28:1673-1678
9. Parikh S, Gut J, IstVan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005; 49:2983-2985
10. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51:424-429
11. Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW. Urbanization, malaria transmission and disease burden in Africa. Nat Rev Microbiol 2005; 3:81-90
12. Carneiro I, Smith L, Ross A, Roca-Feltrer A, Greenwood B, Schellenberg JA, et al. Intermittent preventive treatment for malaria in infants: a decision-support tool for sub-Saharan Africa. Bull World Health Organ 2010; 88:807-814
13. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, Talisuna A, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006; 75:219-225
14. Murray C, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA: Harvard University Press; 1996
15. WHO. Global update on HIV treatment 2013: results, impact and opportunities. Geneva: WHO; 2013. http://www.who.int/hiv/pub/progressreports/update2013/en/[accessed 15 November 2013]
16. Kelly-Hope LA, McKenzie FE. The multiplicity of malaria transmission: a review of entomological inoculation rate measurements and methods across sub-Saharan Africa. Malar J 2009; 8:19
17. Afrane YA, Zhou G, Lawson BW, Githeko AK, Yan G. Life-table analysis of Anopheles arabiensis in western Kenya highlands: effects of land covers on larval and adult survivorship. Am J Trop Med Hyg 2007; 77:660-666
18. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010; 7:e1000324
19. Ijumba JN, Mwangi RW, Beier JC. Malaria transmission potential of Anopheles mosquitoes in the Mwea-Tebere irrigation scheme, Kenya. Med Vet Entomol 1990; 4:425-432
20. Lines JD, Wilkes TJ, Lyimo EO. Human malaria infectiousness measured by age-specific sporozoite rates in Anopheles gambiae in Tanzania. Parasitology 2009; 102:167
21. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: The 2010 revision, Volume 1: Comprehensive Tables. New York: UN, 2011
22. Smith DL, Drakeley CJ, Chiyaka C, Hay SI. A quantitative analysis of transmission efficiency versus intensity for malaria. Nat Commun 2010; 1:108
23. Korenromp EL, Williams BG, de Vlas SJ, Gouws E, Gilks CF, Ghys PD, et al. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis 2005; 11:1410-1419
24. Filipe JAN, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model. PLoS Comput Biol 2005; 3:e255
25. Davidson G, Draper C. Field studies of some of the basic factors concerned in the transmission of malaria. Trans R Soc Trop Med Hyg 1953; 47:522-535
26. Lindblade KA, ONeill DB, Mathanga DP, Katungu J, Wilson ML. Treatment for clinical malaria is sought promptly during an epidemic in a highland region of Uganda. Trop Med Int Health 2000; 5:865-875
27. Briet OJT, Penny MA, Hardy D, Awolola TS, Van Bortel W, Corbel V, et al. Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study. Malar J 2013; 12:77
28. Snow RW, Craig MH, Newton CR, Steketee RW. The public health burden of Plasmodium falciparum malaria in Africa: Deriving the numbers. Working Paper No. 11, Disease Control Priorities Project. Bethesda, MD: Fogarty International Center, National Institutes of Health; 2003
29. Brewster DR, Kwiatkowski D, White NJ. Neurological sequelae of cerebral malaria in children. Lancet 1990; 336:1039-1043
30. Roca-Feltrer A, Carneiro I, Armstrong Schellenberg JR. Estimates of the burden of malaria morbidity in Africa in children unDer the age of 5 years. Trop Med Int Health 2008; 13:771-783
31. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. Am J Trop Med Hyg 2001; 64:57-67
32. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ongecha JM. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci 2011; 7:1427-1442
33. Olliaro P. Editorial commentary: mortality associated with severe Plasmodium falciparum malaria increases with age. Clin Infect Dis 2008; 47:158-160
34. Jagannathan P, Muhindo MK, Kakuru A, Arinaitwe E, Greenhouse B, Tappero J, et al. Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt antimalarial therapy in Tororo, Uganda. Malar J 2012; 11:435
35. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994; 72:429-445
36. UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. 2011. http://www.who.int/hiv/pub/progress-report2011/en/. [accessed 25 November 2013].
37. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 62:229-243
38. Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis 2014; 59:446-453
39. Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011; 342:d1617
40. Ahmed BS, Phelps BR, Reuben EB, Ferris RE. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, lowresource settings? Trans R Soc Trop Med Hyg 2014; 108:49-54
41. Morel CM, Lauer JA, EVans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ 2005; 331:1299
42. Hobbs CV, Tanaka TQ, Muratova O, Van Vliet J, Borkowsky W, Williamson KC, et al. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis 2013; 208:139-148
43. Ikilezi G, Achan J, Kakuru A, Ruel T, Charlebois E, Clark TD, et al. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg 2013; 88:744-746
44. Maganda BA, Minzi OMS, Kamuhabwa AAR, Ngasala B, Sasi PG. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on antiretroviral therapy. Malar J 2014; 13:205
45. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr 2012; 61:310-316
46. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2014; 65:535-541
47. Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234-247
48. Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis 2011; 5:e1325
49. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-Adams TS, Nosten F, Gardiner DL, et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother 2008; 52:2435-2441